转移性去势抵抗性前列腺癌中PSMA PET/CT的缓解评估标准(RECIP 1.0)
这项三中心回顾性研究纳入124例接受177Lu-PSMA治疗的转移性去势抵抗性前列腺癌男性,比较核医学医师定性判读的视觉RECIP与肿瘤分割软件定量RECIP的一致性。视觉与定量RECIP一致性极好(κ=0.89,118/124例,95%),读者间可靠性极好(κ=0.81,103/124例,83%)。RECIP进展与更短总生存相关(HR 2.6,95%CI 1.7-3.8,P<.001),定性RECIP可便捷用于临床实践。
要点
- 视觉RECIP与定量RECIP一致性极好(κ=0.89),读者间可靠性极好(κ=0.81),支持定性判读用于临床。
- RECIP进展(PD)与更短总生存相关(HR 2.6,95%CI 1.7-3.8,P<.001)。
- 视觉RECIP通过定性评估总肿瘤体积变化联合新病灶状态判定,无需分割软件。
核心结论
- 定性评估的RECIP与定量RECIP一致性极好且读者间可靠性极好,可便捷用于接受177Lu-PSMA治疗的转移性去势抵抗性前列腺癌患者的缓解评估。
研究设计与样本
- 多中心回顾性研究,三个学术中心,纳入2014年12月至2019年7月接受177Lu-PSMA治疗的男性124例(中位年龄73岁,IQR 67-76岁),由五名读者对基线和12周PSMA PET/CT图像进行定性评估,并以肿瘤分割软件测量总肿瘤体积的定量变化作为对照。
诊断标准与关键数值
- 视觉RECIP由定性总肿瘤体积变化联合新病灶状态判定,定量RECIP由定量总肿瘤体积变化联合新病灶状态判定;视觉与定量RECIP一致性κ=0.89(118/124例,95%),读者间分类PD与非PD的Fleiss κ=0.81(103/124例,83%);定量RECIP进展40例(32%)、非进展84例(68%);RECIP进展较非进展总生存更短(HR 2.6,95%CI 1.7-3.8,P<.001)。
临床应用与阅片要点
- 核医学医师可依据定性判读总肿瘤体积变化及新病灶状态判定视觉RECIP,与基于分割软件的定量RECIP高度一致,便于临床实施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Response Evaluation Criteria in Prostate-specific Membrane Antigen (PSMA) PET/CT (RECIP 1.0) initially integrated software-based quantitative assessment of PSMA-positive total tumor volume (TTV). Clinical implementation of such software is not expected soon, limiting the use of RECIP in practice. Purpose To assess the agreement of RECIP determined using tumor segmentation software (quantitative RECIP) with RECIP determined by qualitative reads by nuclear medicine physicians (visual RECIP) for response evaluation in metastatic castration-resistant prostate cancer. Materials and Methods This multicenter retrospective study at three academic centers included men who received lutetium 177 (177Lu) PSMA treatment between December 2014 and July 2019. PSMA PET/CT images at baseline and 12 weeks were assessed qualitatively by five readers for changes in TTV and for new lesions. Quantitative changes in TTV were also measured using tumor segmentation software. The status of new lesions was combined with qualitative changes in TTV to determine visual RECIP and with quantitative changes in TTV to determine quantitative RECIP. The primary outcomes were the agreement between visual and quantitative RECIP and the interreader reliability of visual RECIP according to the Fleiss κ. The secondary outcome was the association of visual RECIP with overall survival according to Cox regression. Results A total of 124 men (median age, 73 years [IQR, 67-76 years]) were included. Forty (32%) and 84 (68%) men had quantitative RECIP progressive disease (PD) and non-PD, respectively. Agreement between visual versus quantitative RECIP was excellent (κ = 0.89; 118 of 124 men [95%]). Agreement among readers in classifying visual RECIP PD versus non-PD was excellent (κ = 0.81; 103 of 124 men [83%]). RECIP PD was associated with significantly shorter overall survival compared with non-PD (hazard ratio, 2.6 [95% CI: 1.7, 3.8]; P < .001). Conclusion Qualitatively assessed RECIP demonstrated excellent agreement with quantitative RECIP and excellent interreader reliability and can be readily implemented in clinical practice for response evaluation in men with metastatic castration-resistant prostate cancer undergoing 177Lu-PSMA therapy. © RSNA, 2023 Supplemental material is available for this article.
引用
- Gafita A, Djaileb L, Rauscher I, et al. Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer. Radiology. 2023. PMID: 37432081. doi:10.1148/radiol.222148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。